In today’s recent session, 1.22 million shares of the AnaptysBio Inc (NASDAQ:ANAB) have been traded, and its beta is -0.29. Most recently the company’s share price was $23.48, and it changed around -$7.32 or -23.77% from the last close, which brings the market valuation of the company to $709.10M. ANAB at last check was trading at a discount to its 52-week high of $41.31, offering almost -75.94% off that amount. The share price’s 52-week low was $13.36, which indicates that the recent value has risen by an impressive 43.1% since then. We note from AnaptysBio Inc’s average daily trading volume that its 10-day average is 0.34 million shares, with the 3-month average coming to 322.80K.

AnaptysBio Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.33. If we narrow it down even further, the data shows that 0 out of 8 analysts rate the stock as a Sell; another 4 rate it as Overweight. Among the rest, 0 recommended ANAB as a Hold, whereas 4 deemed it a Buy, and 0 rated it as Underweight. AnaptysBio Inc is expected to report earnings per share of -1.7 for the current quarter.

AnaptysBio Inc (NASDAQ:ANAB) trade information

Instantly ANAB has been showing red trend so far today with a performance of -23.77% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 35.25 on recent trading dayincreased the stock’s daily price by 33.39%. The company’s shares are currently up 9.62% year-to-date, but still down -32.43% over the last five days. On the other hand, AnaptysBio Inc (NASDAQ:ANAB) is -32.55% down in the 30-day period. We can see from the shorts that 5.98 million shares have been sold at a short interest cover period of 20.13 day(s).

The consensus price target as assigned by Wall Street analysts is $41, which translates to bulls needing to increase their stock price by 42.73% from its current value. Analyst projections state that ANAB is forecast to be at a low of $30 and a high of $90.

AnaptysBio Inc (ANAB) estimates and forecasts

AnaptysBio Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -9.76 percent over the past six months and at a -12.50% annual growth rate that is well below the industry average of 17.30%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will loss -20.60% in revenue this quarter, and will report a decrease of -4.40% in the next quarter. The year-over-year growth rate is expected to be 86.90%, up from the previous year.

Consensus estimates provided by 11 financial analysts predict the company will bring in an average of 6.87M in revenue for the current quarter. 11 analysts expect AnaptysBio Inc to make 7.07M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 3.32M and 9.01M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 107.10%. Forecasts for the next quarter put sales growth at -21.50%.

Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -19.45%.

ANAB Dividends

AnaptysBio Inc’s next quarterly earnings report is expected to be released on 2024-Oct-31.

AnaptysBio Inc (NASDAQ:ANAB)’s Major holders

Upon looking at major shareholders, it appears that insiders hold 1.75% of AnaptysBio Inc shares, and 101.41% of them are in the hands of institutional investors. The stock currently has a share float of 103.22%. AnaptysBio Inc stock is held by 198.0 institutions, with ECOR1 CAPITAL, LLC being the largest institutional investor. By 2024-06-30, it held 27.4931% of the shares, which is about 7.52 million shares worth $188.48 million.

FMR LLC, with 10.4936% or 2.87 million shares worth $71.94 million as of 2024-06-30, holds the second largest percentage of outstanding shares.